Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice?
Leigh R; Ellis R; Wattie J; Donaldson DD; Inman MD Firestone Institute for Respiratory Health, St. Joseph’s Healthcare, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada. Interleukin (IL)-13 is regarded as being a central effector in the pathophysiology of airway hyperresponsiveness. We have described a mouse model in which chronic allergen exposure results in sustained airway hyperresponsiveness and aspects of airway remodeling, and here sought to demonstrate that this component of airway hyperresponsiveness is independent of biologically active IL-13. Sensitized mice were subjected to either brief or chronic periods of allergen exposure and studied 24 hours after brief or 4 weeks after chronic allergen inhalation. A soluble murine anti-IL-13 receptor fusion protein that specifically binds to and neutralizes IL-13 was given daily during the 4 days before the day of outcome measurements in both protocols. Outcome measurements included airway responses to intravenous methacholi
